Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) EBT Margin (2016 - 2025)

Tg Therapeutics has reported EBT Margin over the past 10 years, most recently at 32.53% for Q4 2025.

  • Quarterly results put EBT Margin at 32.53% for Q4 2025, down 5687.0% from a year ago — trailing twelve months through Dec 2025 was 0.06% (down 810.0% YoY), and the annual figure for FY2025 was 0.06%, down 810.0%.
  • EBT Margin for Q4 2025 was 32.53% at Tg Therapeutics, down from 16.02% in the prior quarter.
  • Over the last five years, EBT Margin for TGTX hit a ceiling of 68.71% in Q3 2023 and a floor of 100501.25% in Q4 2022.
  • Median EBT Margin over the past 5 years was 164.36% (2023), compared with a mean of 8779.86%.
  • Biggest five-year swings in EBT Margin: surged 22771995bps in 2021 and later tumbled -9645015bps in 2022.
  • Tg Therapeutics' EBT Margin stood at 4051.1% in 2021, then plummeted by -2381bps to 100501.25% in 2022, then surged by 100bps to 31.9% in 2023, then surged by 176bps to 24.34% in 2024, then crashed by -234bps to 32.53% in 2025.
  • The last three reported values for EBT Margin were 32.53% (Q4 2025), 16.02% (Q3 2025), and 21.91% (Q2 2025) per Business Quant data.